ALK-Positive Large B-Cell Lymphoma — Trials

ALK-Positive Large B-Cell Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

5 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 5
Recruiting: 2
Ph III recruiting: 0
Growth YoY: —
Industry share: 20%
Top sponsor: Mayo Clinic
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03038672	Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas	active not recruiting	Phase 2	54	National Cancer Institute (NCI)NIH	1	May 12, 2026	clinicaltrials
NCT05507541	TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma	active not recruiting	Phase 2	10	Mayo ClinicOTHER	1	Apr 22, 2026	clinicaltrials